PMID: 8588697Jul 1, 1995Paper

Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis

Allergy
A LeonardiM Plebani

Abstract

The objectives of this study were to determine: 1) levels of tear eosinophil cationic protein (ECP) in patients with vernal keratoconjunctivitis (VKC); 2) the effect of pharmacologic therapy on ECP release; and 3) the correlation of this mediator with the severity of the disease. Tears were collected from 10 controls and 20 VKC patients before and after therapy for cytologic analysis and ECP measurement by radioimmunoassay. Ocular signs and symptoms were evaluated before tear collection. Mean ECP levels in controls were 7.5 +/- 0.4 microgram/l, and in VKC patients, 988.3 +/- 128 micrograms/l before therapy (P < 0.001) and 566.3 +/- 121 micrograms/l after therapy (P < 0.005). In dexamethasone (Dex) 0.1% or cyclosporin A (CsA) 2% patients (five per group), tear ECP decreased significantly after 7-14 days of treatment. Disodium cromoglycate (DSCG) 4% (five patients) for 14 days did not significantly affect ECP levels. ECP levels were significantly correlated with allergic signs (P < 0.001), symptoms (P < 0.001), and the number of eosinophils in tears (P < 0.005). The results of this study suggest that tear ECP levels accurately reflect the clinical status of VKC patients. The measurement of ECP may prove useful not only in the dia...Continue Reading

References

Sep 1, 1991·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·C G PetersonP Venge
Oct 11, 1990·The New England Journal of Medicine·J BousquetP Godard
Dec 15, 1990·American Journal of Ophthalmology·A G SecchiA Leonardi
Jul 1, 1988·The American Review of Respiratory Disease·K R Patel, E Peers
Sep 1, 1988·The American Review of Respiratory Disease·N A FlavahanP M Vanhoutte
Dec 1, 1988·The American Review of Respiratory Disease·P VengeC G Peterson
Apr 1, 1986·The Journal of Allergy and Clinical Immunology·E Frigas, G J Gleich
Dec 1, 1981·American Journal of Ophthalmology·I J UdellM B Abelson
Jan 1, 1993·Allergy·S BoniniS Bonini
Jan 1, 1992·International Archives of Allergy and Immunology·Sergio BoniniFrancesco Balsano

❮ Previous
Next ❯

Citations

May 9, 2012·Journal of Molecular Evolution·Thomas T WheelerSandeep K Gupta
Jun 7, 2003·Current Allergy and Asthma Reports·Hong ZhanSusan Lightman
Jul 31, 2013·Experimental Eye Research·Andrea Leonardi
Feb 6, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Ellen B CookFrank M Graziano
Sep 25, 2002·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Neri PucciAlberto Vierucci
Mar 12, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·S YoshidaT Tajima
Jul 10, 1999·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·J W OhH B Lee
Jun 8, 2002·Progress in Retinal and Eye Research·Andrea Leonardi
Jan 25, 2003·International Ophthalmology Clinics·Ajay SrivastavaStefan D Trocmé
Jan 25, 2003·International Ophthalmology Clinics·Andrea Leonardi, Antonio G Secchi
Jan 1, 1997·Allergy·S BoniniS Bonini
Jun 1, 1996·The British Journal of Ophthalmology·P G Montan, M van Hage-Hamsten
May 25, 1999·Acta Ophthalmologica Scandinavica. Supplement·A Leonardi
Sep 1, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P VengeA Trulson
Aug 20, 2014·Ophthalmology and Therapy·Andrea Leonardi
Feb 13, 2003·Current Opinion in Allergy and Clinical Immunology·Leonard BieloryTheoharis Theoharides
Sep 1, 2005·Current Opinion in Allergy and Clinical Immunology·Andrea Leonardi
Jul 25, 1998·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·D F AndersonW R Roche
Jun 27, 2012·Progress in Retinal and Eye Research·Lei Zhou, Roger W Beuerman
Nov 1, 2006·The Ocular Surface·Mark B AbelsonMatthew Chapin
Feb 20, 2008·Immunology and Allergy Clinics of North America·Leonard Bielory
Feb 20, 2008·Immunology and Allergy Clinics of North America·Jason JunMichael B Raizman
Mar 5, 2003·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S J Ono
Mar 5, 2003·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·N PucciA Vierucci
Jun 13, 2006·Clinical & Experimental Ophthalmology·Atsuki FukushimaHisayuki Ueno
Oct 4, 2006·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Laura SpadavecchiaLucio Armenio
Sep 13, 2008·Acta Ophthalmologica·Sunil Kumar
Jan 24, 2006·Progress in Retinal and Eye Research·Naoki KumagaiTeruo Nishida
Feb 22, 2000·American Journal of Ophthalmology·A LeonardiM Plebani
Jan 17, 2007·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Adil Kiliç, Bülent Gürler
Aug 25, 2009·Allergology International : Official Journal of the Japanese Society of Allergology·Kazumi FukagawaHirohisa Saito
May 26, 2012·Innate Immunity·Sandeep K GuptaThomas T Wheeler
Dec 12, 2000·The Journal of Allergy and Clinical Immunology·L Bielory
Jan 25, 2003·International Ophthalmology Clinics·Penny A Asbell, Syed M Ahmad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.